TrialSignal
Clinical trial intelligence report
Investigate Differences in SIRT3 Expression in Granulosa Cells and the Levels of Follicular Fluid Metabolites Among Poor Ovarian Responders Subgroups, and Their Association With IVF Outcomes.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 18, 2026
NCT ID
NCT06617988
Status
COMPLETED
Phase
Completed (Observational Study)
Sponsor
Shandong University of Traditional Chinese Medicine
Executive brief
Investment-Ready Snapshot
This observational study, sponsored by Shandong University of Traditional Chinese Medicine, aims to elucidate the role of SIRT3 in differentiating subtypes of poor ovarian response (POR) during IVF. The findings could enhance understanding of ovarian response mechanisms and potentially lead to improved IVF outcomes, thereby addressing a significant market need in reproductive health. The study's focus on metabolic profiling may also open avenues for novel therapeutic strategies targeting metabolic pathways in infertility. Given the increasing demand for personalized medicine in reproductive technologies, the insights gained could position the sponsor favorably within the competitive landscape of fertility treatments.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT06617988
Indication
Poor Ovarian Response
Modality
RNA therapy
Target
SIRT3 expression levels in granulosa cells and associated follicular fluid metabolites.
Intervention
Not applicable- observational study
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.